** Shares of drug developer Fulcrum Therapeutics FULC.O fall 1.8% to $12.75 in extended trading

** FULC kicks off public offering of $150 million worth of shares

** Stock closed 46% higher on Monday after FULC unveiled trial data of blood disorder drug

** J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering

** Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes

** 7 of 9 brokerages rate the stock "buy" or higher, one "hold" and one "sell"; median PT $20 - data compiled by LSEG

** As of last close, FULC up 176.4% YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))